Boston Scientific Co. (NYSE:BSX) Shares Acquired by Advisors Asset Management Inc.

Advisors Asset Management Inc. increased its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 41.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 33,970 shares of the medical equipment provider's stock after purchasing an additional 9,910 shares during the period. Advisors Asset Management Inc.'s holdings in Boston Scientific were worth $3,034,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. TFC Financial Management Inc. increased its stake in Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after buying an additional 210 shares in the last quarter. Dunhill Financial LLC boosted its stake in shares of Boston Scientific by 86.4% in the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 152 shares during the last quarter. Global Wealth Strategies & Associates increased its position in shares of Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 250 shares in the last quarter. West Oak Capital LLC acquired a new position in Boston Scientific in the 4th quarter valued at $29,000. Finally, Valley National Advisers Inc. lifted its holdings in Boston Scientific by 262.4% in the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 286 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Boston Scientific Trading Down 0.7 %

Shares of NYSE:BSX traded down $0.77 during mid-day trading on Wednesday, reaching $102.31. 6,645,633 shares of the company were exchanged, compared to its average volume of 5,794,573. The firm has a market cap of $151.32 billion, a price-to-earnings ratio of 81.85, a P/E/G ratio of 2.79 and a beta of 0.77. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a 1 year low of $66.80 and a 1 year high of $107.17. The firm's 50-day simple moving average is $101.99 and its 200 day simple moving average is $92.80.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities research analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Jeffrey B. Mirviss sold 4,675 shares of the business's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the transaction, the executive vice president now directly owns 28,454 shares of the company's stock, valued at $2,966,329.50. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares in the company, valued at $560,103.60. This represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 137,302 shares of company stock worth $14,319,269 over the last three months. Company insiders own 0.50% of the company's stock.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of research reports. Truist Financial upped their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. Royal Bank of Canada upped their price objective on shares of Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Argus set a $130.00 target price on shares of Boston Scientific in a research note on Tuesday, February 18th. TD Cowen upped their price target on Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, December 12th. Finally, Canaccord Genuity Group increased their price target on Boston Scientific from $98.00 to $101.00 and gave the company a "buy" rating in a report on Monday, December 9th. Two equities research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $108.91.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.